Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at University of Michigan

Sites in Ann Arbor, MI

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1232
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Michigan, Ann Arbor, MI
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Michigan, Ann Arbor, MI. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 493–504 of 1,232 matching trials with a site at University of Michigan, Ann Arbor, MI.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Phase 3 Interventional

Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis

NCT07520110
Site status not listed — check the official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Metformin, Matching Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Conditions
Ewing Sarcoma, Colorectal Adenocarcinoma
Interventions
INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
12 Years to 85 Years
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

NCT04339738
Site status not listed — check the official record
Conditions
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
170
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
Active, not recruiting Not applicable Interventional

PRIMARY Ancillary Substudy

NCT07103733
Site status not listed — check the official record
Conditions
Mitral Valve Prolapse, Left Ventricular Fibrosis, Ventricular Arrhythmias
Interventions
Cardiac Magnetic Resonance Imaging, ZioPatch Monitoring, Myocardial Tissue Biopsy
Procedure · Device
Lead sponsor
Annetine Gelijns
Other
Eligibility
60 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Conditions
Inherited Retinal Degeneration, Retinitis Pigmentosa
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
19
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Recruiting Phase 3 Interventional

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study

NCT06713616
Status at this site: Active, not recruiting
Conditions
Depression
Interventions
Racemic ketamine, Spravato (Esketamine)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 5 more
Recruiting No phase listed Observational

Parkinson's Foundation PD GENEration Genetic Registry

NCT04994015
Status at this site: Active, not recruiting
Conditions
Parkinson's Disease
Interventions
Lab Assay for seven genetic variants for Parkinson's Disease
Device
Lead sponsor
Parkinson's Foundation
Other
Eligibility
18 Years and older
Enrollment
35,382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
63
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 50 more
Conditions
Pancreatic Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
50 Years to 75 Years
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2034
U.S. locations
413
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more
Conditions
Parkinson's Disease
Interventions
Standard of Care
Other
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Tucson, Arizona • Fountain Valley, California + 23 more
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Conditions
Osteoarthritis, Knee, Osteoarthritis of the Knee
Interventions
Placebo, Cannabidiol (CBD), Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)
Drug
Lead sponsor
Steven E Harte, PhD
Other
Eligibility
21 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Recruiting No phase listed Observational

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

NCT07264959
Status at this site: Recruiting
Conditions
Indolent Systemic Mastocytosis
Interventions
Not listed
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
7
States / cities
Aurora, Colorado • Normal, Illinois • Wheaton, Maryland + 4 more

About this University of Michigan institution page

What this page lists
ClinicalTrials.gov records that list University of Michigan in Ann Arbor, MI as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.